Welcome to the e-CCO Library!

P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Guidi1*, D. Pugliese1, T. Panici Tonucci1, B. Tolusso2, C. Felice1, C. Di Mario2, A. Papa1, E. Gremese2, A. Gasbarrini3, G.L. Rapaccini1, A. Armuzzi1

Created: Thursday, 21 February 2019, 9:14 AM
P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Viazis1, E. Tsoukali1, C. Pontas1, G. Karampekos1, F. Gkeros1, G. Filippidis1, M. Vraka1, K. Koustenis1, K. Mountaki1, I. Mitselos2, M. Mela1, A. Christidou1, E. Archavlis1, E. Vienna1, D. Christodoulou2, G. Mantzaris1

Created: Thursday, 30 January 2020, 10:12 AM
P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Piotrowicz G.*1, Kowerzanow J.2, Banaszkiewicz P.2, Babicki A.2, Kot J.3, Rydzewska G.4

Created: Wednesday, 20 February 2019, 10:36 AM
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Bossuyt, P.(2);Baert, F.(3);Molnár, T.(4);Clasquin, E.(1);Lowenberg, M.(1);Montazeri, N.(1);Peeters, H.(5);Lambrecht, G.(6);Vermeire, S.(7);
Created: Friday, 14 July 2023, 11:05 AM
P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Selinger1, G.C. Parkes2*, M. Adamson3, A. Bassi4, F. Donovan5, A. Fraser6, B. George7, L. Grey8, V. Hall9, J. Lindi10, H. Ludlow11, I. Parisi12, P. Patel13, R. Pollock14, S. Salunke15, J. Saunders16, G. Scott17, M. Smith18, T. Raine19

Created: Thursday, 21 February 2019, 9:14 AM
P576: Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
Year: 2022
Source: ECCO'22
Authors: Alsoud, D.(1);Franchimont, D.(2);D'Heygere, F.(3);Bossuyt, P.(4);Vijverman, A.(5);Van Hootegem, P.(6);Sabino, J.(1,7);Cremer, A.(2);Vermeire, S.(1,7);Ferrante, M.(1,7);
Created: Friday, 11 February 2022, 3:56 PM
P576: Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Bertani*1, G. Bodini2, G. Mondello1, M. G. Mumolo3, S. Maltinti1, I. Baldissarro2, G. Tapete1, E. Albano1, L. Ceccarelli3, M. Crespi2, V. Savarino2, S. Marchi1, F. Costa3

Created: Friday, 22 February 2019, 9:41 AM
P576: Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Mateos, B.(1);Sáez-González, E.(2);Iborra, M.(2);Moret, I.(1);Cañada, A.(3);Tortosa, L.(1);Bastida, G.(2);Aguas, M.(2);Cerrillo, E.(2);Nos, P.(2);Beltrán, B.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P577 Ustekinumab in actual clinical practice: our centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M. LOPEZ TOBARUELA, A.D. Sanchez-Capilla, E.J. Ortega-Suazo, M.C. Fernandez-Cano, M. Herrador-Paredes, M.J. Cabello-Tapia, M.M. Martin-Rodriguez

Created: Thursday, 30 January 2020, 10:12 AM
P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bryant R.*1,2, Costello S.1,3, Schoeman S.4, Sathananthan D.4, Lau S.3, Schoeman M.4, Mountifield R.1,5, Tee D.6, Travis S.7,8, Andrews J.1,9

Created: Wednesday, 20 February 2019, 10:36 AM
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Danese, S.(2);Colombel, J.F.(3);Rieder, F.(4);Yarur, A.(5);Verstockt, B.(6);Lichtiger, S.(7);Mosig, R.(8);Cataldi, F.(7);Feagan, B.(9);
Created: Friday, 14 July 2023, 11:05 AM
P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Orlando1*, F.S. Macaluso1, W. Fries2, A.C. Privitera3, M. Cappello4, S. Siringo5, G. Inserra6, A. Magnano7, R. Di Mitri8, N. Belluardo9, G. Scarpulla10, G. Magrì11, N. Trovatello12, A. Carroccio13, S. Genova14, C. Bertolami15, R. Vassallo16, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 21 February 2019, 9:14 AM
P577: Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Lisle1, S. Myers1, D. Pugliese2, T. Raine3, A. C. de Vries4, K. Katsanos5, R. Filip6, K. Karmiris7, S. Sebastian*1,8

Created: Friday, 22 February 2019, 9:41 AM
P577: Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease
Year: 2022
Source: ECCO'22
Authors: Gabriëls, R.Y.(1);Bourgonje, A.R.(1);von Martels, J.(1);Blokzijl, T.(1);Weersma, R.(1);Galinsky, K.(2);Julius, J.(2);Faber, K.N.(1);Kats-Ugurlu, G.(3);Dijkstra, G.(1);
Created: Friday, 11 February 2022, 3:56 PM
P577: Withdrawal of thiopurines in patients with Ulcerative Colitis in remission
Year: 2021
Source: ECCO'21 Virtual
Authors: Amor Costa, C.(1);Suárez Ferrer, C.(1);Poza Cordón, J.(1);Rueda García, J.L.(1);Sánchez Azofra, M.(1);Martín Arranz, E.(1);González Diaz, I.(1);Amiama Roig, C.(1);García Ramirez, L.(1);Martín Arranz, M.D.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P578 Inter-observer agreement of an expert panel for gastrointestinal ultrasound in ulcerative colitis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F. de Voogd1, R. Wilkens2, K. Gecse1, M. Allocca3, K. Novak4, C. Lu4, G. D’Haens1, C. Maaser5, International Bowel UltraSound (IBUS) - Group

Created: Thursday, 30 January 2020, 10:12 AM
P578: Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Borzan, V.(1,2);Orsic Fric, V.(1,2);Borzan, B.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hartery K., Moran C., Sheridan J., Keegan D., Byrne K., Horgan G., Doherty G., Cullen G., Buckley M., Mulcahy H.

Created: Wednesday, 20 February 2019, 10:36 AM
P578: Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panés, J.(1)*;Panaccione, R.(2);Sands, B.(3);Gasink, C.(4);Marano, C.(5);Ma, T.(4);Hoops, T.(6);
Created: Friday, 14 July 2023, 11:05 AM
P578: Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability
Year: 2022
Source: ECCO'22
Authors: Lontai, L.(1);Gonczi, L.(1);Balogh, F.(1);Komlodi, N.(1);Resal, T.(2);Farkas, K.(2);Molnar, T.(2);Golovics, P.(3);Schafer, E.(3);Szamosi, T.(3);Miheller, P.(4);Ilias, A.(1);LakatosPhD, P.L.(1,5);
Created: Friday, 11 February 2022, 3:56 PM